Tag Archives | HCV

FED Rallies Market But Biotech Stocks Are Lagging

Market Rallies on FED comments but Biotechs are Left Behind FED Expected to Raise Rates as Labor Market Tightens The FED stands pat on rates but is on track to raise rates later this year, possibly at the September meeting, as jobs are on track but inflation is still not above 2%. The market began […]

Continue Reading 0

Biotech Mania: Another Deal, Another Rally To New Highs…Update-1

Biotech Stocks More Subdued– as of Mid-Day 7/20 Trading Biotechnology stocks are taking a rest today after a torrid five days that saw the XBI up 7.31%, FBT up 6.19% and the IBB up 6.65%. Moreover on Friday 7/17 the trading in six or more biotech small caps made the “Percentage gainer” tally in the […]

Continue Reading 0

2015 Rayno Biopharmaceutical Stock Portfolio

The Biotech Bull Market Is Now in its Sixth Year Led By Biopharmaceuticals Here is the current Rayno Biopharmaceutical Stock Portfolio as of 7/13 prices: Top winners since inception (2009) are: Regeneron (REGN), Alexion (ALXN) and Biogen (BIIB). Winners 2015 YTD are Fibrocell Sciences (FCSC) up 109%, Seattle Genetics (SGEN) up 47.7%, Celldex Therapeutics (CLDX) […]

Continue Reading 0

Biotech Bull Market Rolls On in a Volatile Q2 2015: XBI Up 12.4%

Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up 12.41% compared to 5% for the […]

Continue Reading 0

Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates

Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its high of $35.50. Update-1 See Chart below of Emerging Orphan drug […]

Continue Reading 0